

# HOUSE RESEARCH

## Bill Summary

**FILE NUMBER:** H.F. 2086

**DATE:** March 8, 2004

**Version:** As introduced

**Authors:** Paymar and others

**Subject:** Prescription drug marketing expense reporting

**Analyst:** Anna Bonelli, 651-296-5808

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: [www.house.mn/hrd](http://www.house.mn/hrd).

---

### Overview

This bill requires prescription drug manufactures to report marketing expenses and provides for penalties for violations.

#### Section

**1 Prescription drug marketing expense reporting.** Adds § 256.9951.

**Subd. 1. Reporting obligations.** Requires prescription drug manufacturers to report specified marketing expenses in Minnesota to the Department of Human Services. The report must describe the nature and target of the activities, and the amount spent on each activity.

**Subd. 2. Enforcement.** Provides penalties for violation and falsification, and gives the Department of Human Services, the Board of Pharmacy, and the Attorney General enforcement authority. The commissioner must share reports made under this section with the Board and the Attorney General.